2023
Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements
D’Amico G, Zipprich A, Villanueva C, Sordà J, Morillas R, Garcovich M, Retortillo M, Martinez J, Calès P, D’Amico M, Dollinger M, García-Guix M, Ballerga E, Tsochatzis E, Cirera I, Albillos A, Roquin G, Pasta L, Colomo A, Daruich J, Canete N, Boursier J, Dallio M, Gasbarrini A, Iacobellis A, Gobbo G, Merli M, Federico A, Baroni G, Pozzoni P, Addario L, Chessa L, Ridola L, Garcia-Tsao G. Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements. Hepatology 2023, 79: 869-881. PMID: 37916970, DOI: 10.1097/hep.0000000000000652.Peer-Reviewed Original ResearchMulticenter cohort studyFurther decompensationLiver transplantFirst decompensationCumulative incidenceCohort studyLarge multicenter cohort studyCause-specific Cox modelsFive-year probabilityHazard ratioPrognostic weightPrognostic indicatorDecompensationCirrhosisCox modelPatientsAdvanced stageTransplantIncidenceMortalityDeathAscitesComplicationsMonths
2020
Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis
Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura‐Cots M, Abraldes JG, Bosques‐Padilla F, Verna EC, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Lucey MR, Louvet A, Mathurin P, Garcia‐Tsao G, Ho SB, Tu XM, Bataller R, Stärkel P, Fouts DE, Schnabl B. Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. Hepatology 2020, 71: 522-538. PMID: 31228214, PMCID: PMC6925657, DOI: 10.1002/hep.30832.Peer-Reviewed Original ResearchConceptsAnti-Saccharomyces cerevisiae antibodiesSerum anti-Saccharomyces cerevisiae antibodiesAlcoholic hepatitisSystemic immune responsesAlcohol use disorderASCA levelsLiver diseaseNonalcoholic controlsImmune responseUse disordersAlcohol-associated liver diseaseAlcohol-related liver diseaseHigher ASCA levelsIntestinal Fungal DysbiosisOvergrowth of CandidaAdjusted hazard ratioCohort of patientsChronic alcohol consumptionIntestinal microbiota compositionIU/mLCerevisiae antibodiesFecal mycobiotaHepatitis cohortHazard ratioSteroid treatment